Subscribe

Bispecific Antibodies

FDA Granted Second Approval for Epkinly to Treat Patients With Relapsed or Refractory Follicular Lymphoma
FDA Updates, Bispecific Antibodies
Web Exclusives
On June 26, 2024, the FDA approved epcoritamab-bysp (Epkinly; Abbvie and Genmab) as the first and only T-cell engaging bispecific antibody administered subcutaneously for the treatment of adults with relapsed or refractory follicular lymphoma (FL) after ≥2 lines of prior therapy. Read More ›
Emerging Immunotherapy Combination Strategies for Breast Cancer: Dual Immune Checkpoint Modulation, Antibody–Drug Conjugates, and Bispecific Antibodies
Breast Cancer, Bispecific Antibodies
2021 Year in Review - HER2-Negative Breast Cancer
Along with surgery, radiation, chemotherapy, and targeted therapy, immunotherapy has emerged as the fifth pillar of cancer treatment and is revolutionizing cancer treatment across the board. Read More ›


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, TON print publication, and TON Bi-Weekly e‑newsletter.

Subscribe

Amplity

© Amplity, Inc. All Rights Reserved. Privacy Policy.

We Value Your Feedback! Tell Us How You Consume Content

Your feedback will help us tailor our content to better meet your needs and preferences.

*First Name
*Last Name
*Email
*What's your favorite format for experiencing our content?